Core Viewpoint - Jiangsu Haooubo Biopharmaceutical Co., Ltd. plans to sell land use rights and factory buildings to Suzhou Xinliancheng Software Co., Ltd. for a total price of 19.52 million yuan, aiming to optimize asset structure and maintain reasonable asset allocation [1][2][11] Transaction Overview - The transaction was approved at the 24th meeting of the third board of directors on August 1, 2025, and does not require shareholder approval [2][4] - The sale involves land use rights and factory buildings located at No. 218 Xinghu Street, Suzhou Industrial Park, with a total transfer price of 19.52 million yuan, including tax [2][3] - The transaction does not constitute a related party transaction or a major asset restructuring [1][4] Buyer Information - The buyer, Suzhou Xinliancheng Software Co., Ltd., was established on October 19, 2016, with a registered capital of 10 million yuan, primarily engaged in software development and sales [4][5] Asset Details - The asset being sold has a book value of 11,070,583.08 yuan as of June 30, 2025, with a historical cost of 17,339,100 yuan [6][5] - The asset is free from any encumbrances, litigation, or other restrictions on transfer [5][6] Valuation and Pricing - The asset was appraised at 19.01 million yuan as of June 19, 2025, resulting in a valuation increase of 71.75% compared to its book value [6][8] - The final transaction price of 19.52 million yuan was determined through negotiation, reflecting a fair and reasonable pricing principle [8][7] Payment and Delivery Terms - The payment structure includes a 95% payment within 30 working days after the contract becomes effective, with the remaining 5% due within 3 days after obtaining the property rights certificate [9][10] - The risk of loss or damage to the property will transfer to the buyer upon delivery or completion of the property rights registration [9][10] Impact on Company - The sale is intended to optimize the company's asset structure and will not affect its normal operations or harm the interests of shareholders, particularly minority shareholders [11]

Group 1 - The company, Haooubo (688656.SH), announced the sale of land use rights and factory buildings located at 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province to Chip Union Company as part of its overall strategic development plan [1] - The sale aims to further optimize the company's asset structure and maintain reasonable asset allocation [1] - The agreed transfer price for the assets, including tax, is 19.52 million yuan, with the final transaction price to be determined by the formal sale contract signed between the company and Chip Union [1]

Core Viewpoint - The company, Haooubo (688656.SH), is selling its land use rights and factory buildings located in Suzhou Industrial Park, Jiangsu Province, to Chip Union Company as part of its overall strategic development plan to optimize asset structure and maintain reasonable asset allocation [1] Group 1 - The asset being sold includes land use rights and factory buildings at a specific address in Suzhou [1] - The total consideration for the asset sale is 19.52 million yuan, which includes tax [1] - The final transaction price will be determined by the formal sale contract signed between the company and Chip Union [1]

Core Viewpoint - Guangdong Ruizhi Environmental Technology Co., Ltd. announced the transfer of 100% equity of its wholly-owned subsidiary, Yunnan Ruizhi New Materials Development Co., Ltd., to Hubei Weide Technology Industrial Co., Ltd. for a price of RMB 19.308 million, aiming to optimize asset structure and improve management efficiency [1]. Group 1 - The equity transfer is part of the company's strategic development needs [1]. - After the completion of the transfer, the company will no longer hold any equity in Yunnan Ruizhi, and it will be excluded from the company's consolidated financial statements [1]. - The asset sale is expected to enhance the company's resource integration and operational efficiency [1].

Financial Data and Key Metrics Changes - Second quarter revenues were $780.9 million, an increase of 4.2% year over year on a GAAP basis and up 1% on an adjusted constant currency basis, exceeding previous guidance of $769 million to $777 million [5][6] - Adjusted earnings per share were $3.73, a 9.1% increase year over year [6][25] - Adjusted gross margin was 59.7%, a decrease of 110 basis points year over year, primarily due to cost inflation and unfavorable product mix [23][24] - Adjusted operating margin was 26.9%, a 20 basis point year over year increase [23][24] Business Line Data and Key Metrics Changes - Americas revenues were $525.7 million, a 2% increase year over year, driven by intra-aortic balloon pumps [7] - EMEA revenues decreased 2.1% year over year to $166.2 million, with strength in Interventional business offset by challenges in Anesthesia [7] - Asia revenues were $89 million, a 1.2% increase year over year, driven by Southeast Asia, India, and Japan [8] - Vascular Access revenue increased 1.4% year over year to $185.5 million, led by growth in PICCs [9] - Interventional revenue was $170 million, a 19.3% increase year over year, driven by intra-aortic balloon pumps and complex catheters [9] - Anesthesia revenues decreased 7.6% year over year to $96.4 million, primarily due to tough comps in military orders [10] - Surgical business revenue increased 1.4% year over year to $114 million, with solid underlying trends [10] Market Data and Key Metrics Changes - The company expects continued revenue improvement in China through the remainder of 2025, despite previously announced volume-based procurement dynamics [8] - The acquisition of the Vascular Intervention business is expected to generate over $800 million in annual revenues [15] Company Strategy and Development Direction - The company is progressing with the separation announced in February, aiming for focused strategic direction and streamlined operations [12][36] - A potential sale of NewCo is being pursued, with significant interest from potential buyers [13][36] - The acquisition of BioTronic's vascular intervention business is a key part of the value creation strategy, expected to enhance global presence and improve patient care [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about operational excellence and value creation, with updated financial guidance reflecting strong performance [5][36] - The company anticipates total constant currency growth for 2025 to be in the range of 7.7% to 8.7%, significantly higher than previous guidance [27][28] - Management highlighted the positive impact of proposed reimbursement changes from CMS on UroLift and Baragel, which could enhance growth prospects [71][72] Other Important Information - Cash flow from operations for the first half of 2025 was $81.2 million, a decrease from $204.5 million in the prior period, primarily due to unfavorable changes in working capital [26] - The company expects a tariff impact of approximately $29 million in 2025, a reduction from previous estimates [30] Q&A Session Summary Question: Can you provide more context on the guidance bridge between tariffs, FX, and business outperformance? - Management indicated that the organic growth expectation for the Biotronic business is mid-single digits for the second half of the year, with overall operational performance contributing positively to EPS [40][41] Question: What is the growth outlook for remainco and newco? - Remainco is expected to grow in the upper 5% range, while newco's interventional business is anticipated to grow high single to low double digits for the full year of 2025 [44][46] Question: Can you discuss the timing and decision-making process for NewCo? - The timing for a potential spin-off is still mid-2026, with ongoing due diligence and interest from potential buyers [50][81] Question: How will the proposed CMS rule impact UroLift? - The proposed rule is expected to provide a 10% uplift in reimbursement for UroLift, which could significantly enhance growth prospects [71][84] Question: What are the expectations for the integration of the BioTronic salesforce? - The integration is expected to leverage existing channels, with significant opportunities for revenue synergies due to the combined sales force [94][95]

透云生物(01332)发布公告，于2025年7月31日，卖方(公司的间接全资附属公司山西透云生物科技有限公 司)与买方(长治市潞城区潞新建设投资集团有限公司)就出售位于山西省长治市潞城区的若干蒸汽管道设 施订立蒸汽管网资产转让协议，代价为人民币1481.7万元。 卖方向买方转让以下目标资产：发电厂内550米中压蒸汽管道及420米冷凝水回收管道;及从发电厂至卖 方位于中国山西省长治市潞城区店上镇常庄村潞城经济技术开发区的厂房边界的1550米中压蒸汽管道、 1550米冷凝水回收管道及配套设施。 根据日期为2020年2月21日的合作协议，区政府同意提供建设设施的相关土地使用权，以支援建设莱茵 衣藻及相关产品设施。于2021年8月20日，目标资产(即作为设施一部分的蒸汽供应管道)的建设已完 成。 为优化蒸汽供应管道的使用及支援潞城区的工业发展，买方(作为区政府的代表)拟收购目标资产。完成 后，目标资产将成为该区公共基础设施的一部分，确保区内所有厂房公平使用。 经考虑集团将收取的代价，董事会认为，集团进行出售事项乃属恰当。出售事项落实后，可加强集团的 现金流量，使集团得以改善其流动资金，并让集团可重新分配其资源作未来发 ...

目标为一间根据香港法律注册成立的公司。目标集团主要于内地从事媒体及娱乐服务。 格隆汇7月31日丨亚洲电视控股(00707.HK)发布公告，于2025年7月31日，卖方（公司全资附属公司）与 买方订立该协议，出售亚洲电视(中国)控股有限公司的100%股权，完成后须支付代价100,000港元。 目标集团于过去三个财政年度一直录得亏损，而过去一个财政年度录得负债净额。公司拟出售亏损业 务，并将资源集中表现良好的分类，以改善集团的财务状况。 ...

格隆汇7月31日丨中国飞机租赁(01848.HK)公告，董事会欣然宣布，为提升资本利用率及追求长期可持 续增长，于2025年7月31日，公司全资附属特殊目的实体(卖方)与独立第三方(买方)就出售八架连租约飞 机订立《飞机组合及资产买卖协议》，其中包括由集团拥有的六架飞机以及由集团管理的两架飞机。出 售事项预期于2025年10月底前完成。 ...

解決不發表意見一事的計劃及措施的落實進展 中國文旅農業集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）謹此提供有關本集團為減緩本集團的流動性壓力及解決本公司 核 數 師 就 持 續 經 營 不 發 表 意 見 一 事 落 實 的 計 劃 及 措 施（「計 劃 及 措 施」， 具 體 內 容 載於本公司截至二零二 四年十二月三十一日止年度的年報（「年報」）第37頁 ）的進 展。除另有界定者外，本公告所用詞彙與年報所界定者具有相同涵義。 直至本公告日期計劃及措施的落實情況概述如下： 本公司將適時根據上市規則及╱或聯交所之要求就計劃及措施的進展刊發公告。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Cultural Tourism and Agriculture Group Limited 中 國 文 旅 農 業 集 團 有 限 公 ...

Core Viewpoint - The sale of Li Ka-shing's global port assets to a US consortium, with the involvement of Chinese mainland investors, represents a strategic move to ensure profitability for all parties involved in the transaction [3][7]. Group 1: Transaction Details - On July 28, Cheung Kong Holdings announced plans to invite major strategic investors from mainland China to join the sale of its port assets, emphasizing that no transactions would occur without regulatory approvals [3]. - The deal involves the sale of 80% of Cheung Kong's port assets and 90% of its Panama port company, expected to generate $19 billion in cash for the company [5]. - The consortium led by BlackRock and Italian shipping magnate Gianluigi Aponte's "Port Investment Company" is involved in the transaction, which includes 43 ports across 23 countries [5][6]. Group 2: Strategic Implications - The entry of China Ocean Shipping Group (COSCO) into the deal is seen as a stabilizing factor, providing a satisfactory price reference and potentially enhancing the transaction's viability [7][8]. - The transaction is viewed as a win-win situation, with COSCO's involvement allowing for strategic asset acquisition while BlackRock seeks quality assets and stable returns [7][8]. Group 3: Historical Context - Li Ka-shing has been considering the sale of port assets since at least 2015, with previous valuations suggesting a price of 150 billion HKD for 40% of the port business, which aligns closely with the current deal's valuation [8]. - The port business has been a core asset for Li Ka-shing, with a global presence that includes 295 berths across 53 ports in 24 countries, excluding mainland and Hong Kong ports [16][18]. Group 4: Financial Overview - As of the 2024 financial report, Cheung Kong Holdings has total assets of $83.137 billion, with the port assets being valued at $14.212 billion, representing 17.1% of the company's net assets [18][19]. - The port business contributes only 9% to the overall revenue of Cheung Kong, indicating a mismatch between asset value and revenue contribution, which may have influenced the decision to sell [19].